Mitochondria-Targeting Peptide SS-31 Protected Brain Cells After Traumatic Injury in Mice
The peptide SS-31 reversed mitochondrial damage and reduced brain swelling, cell death, and neurological deficits when given 30 minutes after traumatic brain injury in mice.
Quick Facts
What This Study Found
The mitochondria-targeted peptide SS-31 (elamipretide) provided significant neuroprotection after traumatic brain injury in mice when administered 30 minutes post-injury. SS-31 reversed mitochondrial dysfunction by reducing reactive oxygen species, restoring superoxide dismutase activity, decreasing oxidative damage markers (MDA), and preventing cytochrome c release.
This translated to reduced neurological deficits, brain swelling, DNA damage, and neural cell death. Mechanistically, SS-31 restored SIRT1 expression and promoted PGC-1α nuclear translocation, suggesting it enhanced mitochondrial biogenesis — the creation of new, healthy mitochondria to replace damaged ones.
Key Numbers
5 mg/kg SS-31 · IP injection 30 min post-TBI · 24-hour endpoint · Reduced ROS, MDA, cytochrome c · Restored SOD, SIRT1, PGC-1α · Decreased brain edema and apoptosis
How They Did This
Mouse study using a modified Marmarou weight-drop model of traumatic brain injury. Mice were randomized to sham, TBI, TBI+vehicle, or TBI+SS-31 (5 mg/kg IP, 30 min post-injury). Brain tissue was harvested at 24 hours for analysis of mitochondrial function markers, oxidative stress (ROS, SOD, MDA), cytochrome c release, SIRT1/PGC-1α expression (Western blot, immunohistochemistry), brain water content, DNA damage, and neuronal apoptosis.
Why This Research Matters
Traumatic brain injury is a leading cause of death and disability with no approved neuroprotective drugs. SS-31's ability to rapidly restore mitochondrial function after injury addresses a critical therapeutic gap. If these findings translate to humans, this peptide could be administered in emergency settings to limit the secondary brain damage that follows the initial injury.
The Bigger Picture
SS-31 (also known as elamipretide or Bendavia) is being studied for multiple conditions involving mitochondrial dysfunction, including heart failure and rare mitochondrial diseases. This study extends its potential to traumatic brain injury, a condition affecting millions annually with no approved neuroprotective treatment. The SIRT1/PGC-1α pathway activation suggests SS-31 doesn't just protect existing mitochondria but promotes mitochondrial renewal.
What This Study Doesn't Tell Us
Single-dose, single-timepoint mouse study with assessment at only 24 hours post-injury. Long-term neurological outcomes and dose-response relationships were not evaluated. The weight-drop TBI model has limitations in replicating the heterogeneity of human brain injuries. Translation from mouse to human TBI has historically been challenging.
Questions This Raises
- ?Does SS-31 provide neuroprotection when administered hours rather than minutes after TBI?
- ?Would repeated SS-31 dosing improve long-term neurological recovery beyond the 24-hour endpoint?
- ?Is the SIRT1/PGC-1α pathway essential for SS-31's neuroprotective effect, or is ROS scavenging sufficient?
Trust & Context
- Key Stat:
- Mitochondria restored SS-31 reversed mitochondrial dysfunction and promoted new mitochondria creation via SIRT1/PGC-1α pathway after TBI
- Evidence Grade:
- This is a single-species, single-timepoint animal study. While the results are comprehensive and mechanistically detailed, TBI neuroprotection has notoriously failed to translate from animal models to human trials, warranting caution.
- Study Age:
- Published in 2018, this study is part of ongoing preclinical research into SS-31/elamipretide. The peptide continues to be investigated in clinical trials for mitochondrial diseases and cardiac conditions.
- Original Title:
- SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury.
- Published In:
- Oxidative medicine and cellular longevity, 2018, 4783602 (2018)
- Authors:
- Zhu, Yihao, Wang, Handong, Fang, Jiang, Dai, Wei, Zhou, Jiang, Wang, Xiaoliang, Zhou, Mengliang
- Database ID:
- RPEP-04018
Evidence Hierarchy
Frequently Asked Questions
What is SS-31 and how does it work?
SS-31 (also called elamipretide) is a small synthetic peptide designed to concentrate inside mitochondria — the energy factories of cells. It scavenges toxic reactive oxygen species, stabilizes the mitochondrial membrane, and promotes the creation of new healthy mitochondria. In this study, it protected brain cells from the secondary damage that follows traumatic brain injury.
Why is mitochondrial dysfunction important in brain injuries?
After the initial physical impact of a brain injury, mitochondria in brain cells malfunction over the following hours and days. They release toxic molecules, stop producing energy efficiently, and trigger cell death programs. This 'secondary injury' causes much of the long-term brain damage from TBI. Targeting mitochondria with peptides like SS-31 aims to interrupt this destructive cascade.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04018APA
Zhu, Yihao; Wang, Handong; Fang, Jiang; Dai, Wei; Zhou, Jiang; Wang, Xiaoliang; Zhou, Mengliang. (2018). SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury.. Oxidative medicine and cellular longevity, 2018, 4783602. https://doi.org/10.1155/2018/4783602
MLA
Zhu, Yihao, et al. "SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury.." Oxidative medicine and cellular longevity, 2018. https://doi.org/10.1155/2018/4783602
RethinkPeptides
RethinkPeptides Research Database. "SS-31 Provides Neuroprotection by Reversing Mitochondrial Dy..." RPEP-04018. Retrieved from https://rethinkpeptides.com/research/zhu-2018-ss31-provides-neuroprotection-by
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.